JP2020518600A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020518600A5 JP2020518600A5 JP2019559836A JP2019559836A JP2020518600A5 JP 2020518600 A5 JP2020518600 A5 JP 2020518600A5 JP 2019559836 A JP2019559836 A JP 2019559836A JP 2019559836 A JP2019559836 A JP 2019559836A JP 2020518600 A5 JP2020518600 A5 JP 2020518600A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- preparation according
- approximately
- tigit antibody
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023189493A JP2024016177A (ja) | 2017-05-02 | 2023-11-06 | 単独のおよびプログラム死受容体１（ｐｄ－１）抗体と組み合わされた抗ｔｉｇｉｔ抗体の安定な製剤、ならびにその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762500278P | 2017-05-02 | 2017-05-02 | |
| US62/500,278 | 2017-05-02 | ||
| PCT/US2018/030516 WO2018204405A1 (en) | 2017-05-02 | 2018-05-01 | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023189493A Division JP2024016177A (ja) | 2017-05-02 | 2023-11-06 | 単独のおよびプログラム死受容体１（ｐｄ－１）抗体と組み合わされた抗ｔｉｇｉｔ抗体の安定な製剤、ならびにその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020518600A JP2020518600A (ja) | 2020-06-25 |
| JP2020518600A5 true JP2020518600A5 (enExample) | 2021-05-20 |
| JP7402693B2 JP7402693B2 (ja) | 2023-12-21 |
Family
ID=64016405
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019559836A Active JP7402693B2 (ja) | 2017-05-02 | 2018-05-01 | 単独のおよびプログラム死受容体１（ｐｄ－１）抗体と組み合わされた抗ｔｉｇｉｔ抗体の安定な製剤、ならびにその使用方法 |
| JP2023189493A Pending JP2024016177A (ja) | 2017-05-02 | 2023-11-06 | 単独のおよびプログラム死受容体１（ｐｄ－１）抗体と組み合わされた抗ｔｉｇｉｔ抗体の安定な製剤、ならびにその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023189493A Pending JP2024016177A (ja) | 2017-05-02 | 2023-11-06 | 単独のおよびプログラム死受容体１（ｐｄ－１）抗体と組み合わされた抗ｔｉｇｉｔ抗体の安定な製剤、ならびにその使用方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20200354453A1 (enExample) |
| EP (1) | EP3618855A4 (enExample) |
| JP (2) | JP7402693B2 (enExample) |
| KR (1) | KR102770786B1 (enExample) |
| CN (1) | CN110603052A (enExample) |
| AU (1) | AU2018261080A1 (enExample) |
| BR (1) | BR112019022698A2 (enExample) |
| CA (1) | CA3061050A1 (enExample) |
| CL (1) | CL2019003145A1 (enExample) |
| CO (1) | CO2019012356A2 (enExample) |
| IL (1) | IL270175B2 (enExample) |
| MA (1) | MA50661A (enExample) |
| MX (1) | MX2019013033A (enExample) |
| SG (2) | SG11201909941QA (enExample) |
| WO (1) | WO2018204405A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5191537B2 (ja) | 2007-06-18 | 2013-05-08 | エム・エス・ディー・オス・ベー・フェー | ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体 |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| WO2017030823A2 (en) * | 2015-08-14 | 2017-02-23 | Merck Sharp & Dohme Corp. | Anti-tigit antibodies |
| US11021537B2 (en) | 2017-05-01 | 2021-06-01 | Agenus Inc. | Anti-TIGIT antibodies and methods of use thereof |
| AU2018263868A1 (en) | 2017-05-02 | 2019-12-12 | Merck Sharp & Dohme Llc | Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies |
| IL277095B2 (en) * | 2018-03-07 | 2025-10-01 | Pfizer | Preparations containing anti-PD-1 antibody |
| JP7467438B2 (ja) | 2018-10-18 | 2024-04-15 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗ｒｓｖ抗体の製剤及びその使用方法 |
| CN113015748B (zh) | 2018-10-31 | 2025-12-12 | 默沙东有限责任公司 | 抗人pd-1抗体晶体及其使用方法 |
| CN113316458B (zh) | 2018-11-07 | 2024-08-02 | 默沙东有限责任公司 | 抗lag3抗体和抗pd-1抗体的共制剂 |
| WO2020097141A1 (en) * | 2018-11-07 | 2020-05-14 | Merck Sharp & Dohme Corp. | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
| KR20210104736A (ko) * | 2018-12-14 | 2021-08-25 | 모르포시스 아게 | 항체 제형 |
| AU2020290916A1 (en) * | 2019-06-13 | 2021-11-04 | Green Cross Corporation | Antibody to TIGIT and use thereof |
| WO2021013689A1 (en) * | 2019-07-19 | 2021-01-28 | Ichnos Sciences SA | Lyophilized antibody formulation |
| CN112741804A (zh) * | 2019-10-31 | 2021-05-04 | 上海君实生物医药科技股份有限公司 | 含有抗pd-l1抗体的稳定制剂 |
| EP4094777A4 (en) * | 2020-01-21 | 2024-01-24 | Innovent Biologics (Suzhou) Co., Ltd. | RECOMBINANT FULLY HUMAN MONOCLONAL ANTI-TIGITE ANTIBODIES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF |
| EP4093435A1 (en) | 2020-01-24 | 2022-11-30 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| CN114507284B (zh) * | 2020-05-09 | 2023-05-26 | 华博生物医药技术（上海）有限公司 | 抗tigit的抗体、其制备方法和应用 |
| CR20220611A (es) * | 2020-06-02 | 2023-06-07 | Arcus Biosciences Inc | Anticuerpos anti-tigit |
| IL298946A (en) | 2020-06-18 | 2023-02-01 | Genentech Inc | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists |
| CN111718415B (zh) * | 2020-07-03 | 2021-02-23 | 上海洛启生物医药技术有限公司 | 一种抗tigit纳米抗体及其应用 |
| TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷 |
| WO2022146947A1 (en) * | 2020-12-28 | 2022-07-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| CN114762678B (zh) * | 2021-01-14 | 2024-03-15 | 上海君实生物医药科技股份有限公司 | 抗tigit抗体药物组合物及其用途 |
| EP4284834A1 (en) | 2021-01-29 | 2023-12-06 | Merck Sharp & Dohme LLC | Compositions of programmed death receptor 1 (pd-1) antibodies and methods of obtaining the compositions thereof |
| TW202304965A (zh) | 2021-05-04 | 2023-02-01 | 美商艾吉納斯公司 | 抗ｔｉｇｉｔ抗體、抗ｃｄ９６抗體及其使用方法 |
| KR20240038043A (ko) * | 2021-07-23 | 2024-03-22 | 아케소 바이오파마, 인크. | 약학적 조성물 및 용도 |
| JP2024527049A (ja) | 2021-07-28 | 2024-07-19 | ジェネンテック， インコーポレイテッド | がんを治療するための方法及び組成物 |
| WO2023056403A1 (en) | 2021-09-30 | 2023-04-06 | Genentech, Inc. | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
| CN114106182B (zh) * | 2022-01-26 | 2022-05-17 | 中山康方生物医药有限公司 | 抗tigit的抗体及其用途 |
| EP4482868A4 (en) * | 2022-02-24 | 2026-03-04 | Merck Sharp & Dohme Llc | STABLE FORMULATIONS OF A MULTIVALENT, VHH-BASED, CYTOTOXIC, T-LYMPHOCYTE-ASSOCIATED ANTIGEN 4 (CTLA4) BINDING TO HUMANE CTLA4, AND METHOD FOR USE THEREMISSION |
| CA3248502A1 (en) * | 2022-04-14 | 2023-10-19 | Beigene Switzerland Gmbh | Stable and highly concentrated arginine formulations containing a PD-1 antibody and related methods of use |
| IL317449A (en) | 2022-06-07 | 2025-02-01 | Genentech Inc | Method for determining the efficacy of a lung cancer treatment comprising an anti-PD-L1 antagonist and an anti-TIGIT antibody-antagonist |
| US20250362305A1 (en) * | 2022-08-04 | 2025-11-27 | Merck Sharp & Dohme Llc | Methods for determining one or more critical quality attributes of co-formulated antibodies |
| WO2024140651A1 (zh) * | 2022-12-27 | 2024-07-04 | 上海复宏汉霖生物技术股份有限公司 | 包含抗tigit抗体的药物制剂 |
| WO2025166550A1 (zh) * | 2024-02-06 | 2025-08-14 | 香港北恒生物科技有限公司 | 工程化细胞及其用途 |
| CN121003695A (zh) * | 2024-05-24 | 2025-11-25 | 百奥泰生物制药股份有限公司 | 抗tigit抗体和抗pd-1抗体联合治疗肿瘤 |
| WO2025248110A1 (en) | 2024-05-31 | 2025-12-04 | Replimune Limited | An oncolytic herpes simplex virus (hsv) and an anti-pd-1 antibody for use in treating braf mutant melanoma |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2665567C (en) * | 2006-10-06 | 2012-07-03 | Amgen Inc. | Stable formulations |
| US20120183531A1 (en) * | 2009-07-14 | 2012-07-19 | Biogen Idee Ma Inc | Methods for Inhibiting Yellow Color Formation in a Composition |
| EP2399604A1 (en) * | 2010-06-25 | 2011-12-28 | F. Hoffmann-La Roche AG | Novel antibody formulation |
| CA2830806C (en) * | 2011-03-31 | 2020-05-12 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments |
| US20140227250A1 (en) * | 2012-08-23 | 2014-08-14 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to tslp |
| AU2014290069B2 (en) * | 2013-07-16 | 2019-01-03 | Genentech, Inc. | Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors |
| MY198017A (en) * | 2014-08-19 | 2023-07-26 | Merck Sharp & Dohme | Anti-tigit antibodies |
| AR103268A1 (es) * | 2014-12-23 | 2017-04-26 | Bristol Myers Squibb Co | Anticuerpos contra tigit |
| AU2016322934A1 (en) | 2015-09-14 | 2018-04-12 | Compass Therapeutics Llc | Compositions and methods for treating cancer via antagonism of the CD155/TIGIT pathway and TGF-beta |
| EP3394099A4 (en) * | 2015-12-22 | 2019-11-27 | Merck Sharp & Dohme Corp. | Formulations of Manipulated Anti- IL-10 Antibodies |
| US10421811B2 (en) * | 2016-04-25 | 2019-09-24 | Medimmune, Llc | Compositions comprising coformulation of anti-PD-L1 and anti-CTLA-4 antibodies |
| CA3060695A1 (en) * | 2017-05-02 | 2018-11-08 | Merck Sharp & Dohme Corp. | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
-
2018
- 2018-05-01 US US16/610,188 patent/US20200354453A1/en not_active Abandoned
- 2018-05-01 AU AU2018261080A patent/AU2018261080A1/en not_active Abandoned
- 2018-05-01 WO PCT/US2018/030516 patent/WO2018204405A1/en not_active Ceased
- 2018-05-01 EP EP18793797.4A patent/EP3618855A4/en active Pending
- 2018-05-01 KR KR1020197035375A patent/KR102770786B1/ko active Active
- 2018-05-01 IL IL270175A patent/IL270175B2/en unknown
- 2018-05-01 SG SG11201909941Q patent/SG11201909941QA/en unknown
- 2018-05-01 JP JP2019559836A patent/JP7402693B2/ja active Active
- 2018-05-01 MX MX2019013033A patent/MX2019013033A/es unknown
- 2018-05-01 SG SG10202111905PA patent/SG10202111905PA/en unknown
- 2018-05-01 CA CA3061050A patent/CA3061050A1/en active Pending
- 2018-05-01 BR BR112019022698A patent/BR112019022698A2/pt unknown
- 2018-05-01 CN CN201880029167.7A patent/CN110603052A/zh active Pending
- 2018-05-01 MA MA050661A patent/MA50661A/fr unknown
-
2019
- 2019-10-30 CL CL2019003145A patent/CL2019003145A1/es unknown
- 2019-11-01 CO CONC2019/0012356A patent/CO2019012356A2/es unknown
-
2023
- 2023-11-06 JP JP2023189493A patent/JP2024016177A/ja active Pending
-
2024
- 2024-01-25 US US18/422,352 patent/US20240182573A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020518600A5 (enExample) | ||
| JP2024016177A5 (enExample) | ||
| US20240182573A1 (en) | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| JP2020518598A5 (enExample) | ||
| JP2023109942A5 (enExample) | ||
| US20250074985A1 (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| JP6014116B2 (ja) | ヒト・プログラム死受容体ｐｄ−１に対する抗体の安定製剤および関連治療 | |
| JP2020509031A5 (enExample) | ||
| JP2016533335A5 (enExample) | ||
| CN111971062A (zh) | 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途 | |
| RU2012131099A (ru) | Препарат антитела | |
| HRP20201345T1 (hr) | Protutijela koja snažno neutraliziraju virus hepatitisa b i njihova upotreba | |
| EA031436B1 (ru) | Водная фармацевтическая композиция, содержащий ее предварительно заполненный шприц и применение композиции в лечении аутоиммунных заболеваний | |
| CN111050791A (zh) | 用于抗tim-3抗体的给药方案及其用途 | |
| JPWO2019209995A5 (enExample) | ||
| JP2018529328A5 (enExample) | ||
| RU2024131867A (ru) | Фармацевтические составы анти-ilt4 антитела или его антигенсвязывающего фрагмента и способы применения | |
| RU2024131854A (ru) | Стабильные составы анти-ilt4 антител или их антигенсвязывающих фрагментов в комбинации с анти-pd-1 антителами и способы их применения | |
| WO2025056014A1 (zh) | 包含抗pd-1抗体和第二抗体的药物组合物 | |
| RU2024133531A (ru) | Стабильные высококонцентрированные составы на основе аргинина, содержащие антитело к pd-1, и способы их применения | |
| AR130954A1 (es) | Composiciones de anticuerpo anti-ctla y métodos relacionados | |
| JPWO2022241148A5 (enExample) | ||
| TW202229333A (zh) | 冠狀病毒結合分子及其使用方法 | |
| WO2025056011A1 (zh) | 包含抗pd-1抗体和第二抗体的药物组合物 | |
| RU2020126721A (ru) | Антитела к pac1 и варианты их применения |